Homoharringtonine for the treatment of chronic myelogenous leukemia.

Homoharringtonine for the treatment of chronic myelogenous leukemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Homoharringtonine for the treatment of chronic myelogenous leukemia. Abstract Text:

Alfonso ,Jorge Cortes,Alfonso ,Jorge Cortes,

Background: The anticancer activity of the natural alkaloid homoharringtonine (HHT) was first recognized by Chinese investigators. HHT exerts its activity through inhibition of protein synthesis and promotion of apoptosis. Methods: The authors reviewed the most relevant preclinical and clinical studies involving patients with chronic myelogenous leukemia (CML) receiving therapy with either natural HHT or omacetaxine mepesuccinate (Ceflatonin, Myelostat, CGX-653), a semisynthetic subcutaneously bioavailable form of HHT presently under development for the treatment of CML. Results: Prior to the advent of the tyrosine kinase inhibitor (TKI) imatinib mesilate, controlled clinical studies established HHT as the most active therapy in CML after failure of IFN-a for patients who were not candidates for allogeneic stem cell transplantation. Preliminary results from Phase II studies suggest that omacetaxine mepesuccinate is active in patients with imatinib-resistant CML, including those carrying the T315I mutation, which renders imatinib and second-generation TKIs ineffective. Conclusion: These encouraging results have propelled the development of several Phase II/III trials both in Europe and in the US to further delineate the activity of omacetaxine mepesuccinate in patients with CML who are resistant to TKI therapy.

Homoharringtonine for the treatment of chronic myelogenous leukemia. Publishing Authors By Initials

A ,J Cortes,A ,J Cortes,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Homoharringtonine for the treatment of chronic myelogenous leukemia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Expert opinion on pharmacotherapy

VOLUME: 9

Page Numbers: 1029-37

Journal Abbreviation:

ISSN: 1744-7666

DAY: 1

MONTH: Apr

YEAR: 2008

Homoharringtonine for the treatment of chronic myelogenous leukemia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100897346

Homoharringtonine for the treatment of chronic myelogenous leukemia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Homoharringtonine for the treatment of chronic myelogenous leukemia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Homoharringtonine for the treatment of chronic myelogenous leukemia.

AFFILIATION: MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd., Houston, TX 77030, USA +1 713 792 0077 ; +1 713 792 5640 ; aquintas@mdanderson.org.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Opin Pharmacother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Homoharringtonine for the treatment of chronic myelogenous leukemia Related Publications

• Acute lung injury associated with docetaxel and bevacizumab.
• Capillary flow technology with multi-dimensional gas chromatography for trace analysis of oxygenated compounds in complex hydrocarbon matrices.
• Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
• Chronic ethanol consumption in rats produces residual increases in anxiety 4 months after withdrawal.
• Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
• E08 New tyrosine kinase inhibitors in chronic myeloid leukemia (CML).
• Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy.
• Gait pattern normalization after lateral retinaculum reconstruction for iatrogenic medial patellar instability.
• Hepatocellular carcinoma.
• Homoharringtonine for the treatment of chronic myelogenous leukemia.
• Hypolaetin-8-O-Glucoside, An Anti-inflammatory Flavonoid from Sideritis mugronensis.
• Inferior Vena Cava Anomalies during Laparoscopic Retroperitoneal Lymph Node Dissection.
• Instability of hexane-acetonitrile mobile phases used for the chromatographic analysis of triacylglycerides.
• Knee Pain An Unusual Running Injury: 1090: June 1 9:00 AM 9:20 AM.
• Management of diaphragmatic injury during transperitoneal laparoscopic urological procedures.
• Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
• Nilotinib therapy in chronic myelogenous leukemia.
• Pediculosis in Macaca sylvanus of Gibraltar.
• Protection of halogenated DNA from strand breakage and sister-chromatid exchange induced by the topoisomerase I inhibitor camptothecin.
• Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review.
• Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain.
• Situated robotics: from learning to teaching by imitation.
• Tormentic Acid, a New Hypoglycemic Agent from Poterium ancistroides.
• [Aerial image in mediastinum]
• [Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV).]
• [Not Available.]
• [Not Available.]
• [Pseudotumoral adenomyomatosis of the gallbladder diagnosed by ultrasound: Report of one case.]
• [Strabismus and congenital cataracts]
• [Therapeutic approach to Staphylococcus aureus bacteremia]